Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00505843 | A Study of MK0657 in Parkinson's Disease Patients (0657-006) | PHASE1 | COMPLETED | 18 | — | — | May 1, 2007 | Feb 1, 2008 | Jan 29, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | 7mg MK0657 capsules + \>/=1.0 mg/kg/hr dose of levodopa. |
| 2 | OTHER | 7mg MK0657 Pbo capsules + \>/=1.0 mg/kg/hr dose of levodopa. |
| Name | Type | Description |
|---|---|---|
| MK0657 | DRUG | 7mg MK0657 capsules |
| Comparator: Placebo (unspecified) | DRUG | 7mg MK0657 Pbo capsules |
| Comparator: levodopa | DRUG | levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period |
| Comparator: carbidopa | DRUG | carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion. |
Inclusion Criteria: * Parkinson's Disease patients between the ages of 40 and 80 inclusive * Patient is in general good health based on screening assessments * Patient is willing to discontinue anti-parkinson's medications at least 8 hours prior to dosing * Patient is levodopa responsive with levod...